tbuckley/cabot-search huggingface dataset:
Amélioration d’un système national de surveillance de santé publique par l’action d’un quality circle
Authors: G Krause, J Benzler, G Reiprich, R Görgen
Journal: Eurosurveillance (2006)

Les systemes de surveillance des maladies infectieuses constituent une base essentielle pour la mise en œuvre de mesures efficaces de sante publique en termes de prevention et controle de ces maladies. L’evaluation et l’amelioration de la qualite des systemes de surveillance nationaux sont un defi, compte-tenu du nombre d’administrations et de professions contribuant a un systeme complexe par lequel des informations sensibles doivent etre echangees de maniere fiable et rapide. Une evaluation multidisciplinaire, quality circle, du systeme national allemand de sante public a ete organisee, incluant des cliniciens, des medecins de laboratoire et du personnel de services sanitaires locaux et nationaux, ainsi que de l’institut Robert-Koch. Les recommandations faites a l’issue de ce quality circle incluent des modifications de la loi federale de controle des maladies infectieuses ainsi que des changements concernant des activites pratiques telles que le changement des formulaires de notification et l’envoi de lettres d’information par fax aux cliniciens. Un certain nombre de ces recommandations ont ete mises en place depuis, permettant des ameliorations notables pour certaines. Cette experience montre que l’application de la methode du quality circle constitue un outil utile pour ameliorer la qualite des systemes nationaux de surveillance de sante publique.
Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Authors: Simon N. Powell
Journal: Cancer Research (2010)

Abstract The breast cancer susceptibility gene, BRCA2, mediates homologous recombination (HR) via its direct interaction with the Rad51 recombinase. There is ample genetic and biological evidence that BRCA1 and BRCA2 are functioning in the same pathway of DNA repair, but the functional connection between the two proteins is poorly understood. Interestingly, a mutation of BRCA1 (S988A) localized normally to ionizing radiation induced nuclear foci (IRIF), but the BRCA2 protein could not be recruited to BRCA1 at the damage site. Phosphorylation of BRCA1 at the S988 site is carried out by Chk2, which was also required for BRCA2 to localize to sites of DNA damage and support homologous recombination. These observations suggest that CHK2-BRCA1-BRCA2-Rad51 function in a single pathway of homologous recombinational repair to prevent the development of breast cancer. In familial breast cancer, one allele of BRCA1 or BRCA2 is germline mutant and the second allele is inactivated to allow tumor development. Thus, loss of function of BRCA1/BRCA2 is a tumor-specific finding, making the role of alternative repair pathways in these cells critical for their survival. We show that loss of Rad52 function is synthetic lethal with BRCA2 deficiency, whereas there is no impact on cell growth in BRCA2-complemented cells. The frequency of both spontaneous and double-strand break-induced homologous recombination, and ionizing radiation induced Rad51 foci, decreased by greater than 50%, when Rad52 was depleted in BRCA2-deficient cells, with no effect in BRCA2-complemented cells. Ionizing radiation-induced and S-phase associated Rad52-Rad51 foci form equally well in the presence or absence of BRCA2, indicating that Rad52 can respond to DNA double strand breaks and replication stalling independently of BRCA2. The observation that Rad52-inactivation is synthetic lethal with BRCA2 and that Rad52 acts independently of BRCA2 makes Rad52 a target for therapy in these tumors. Finally, we have evidence that the BRCA1-BRCA2 pathway can be functionally inactivated in sporadic breast cancer, suggesting that the pool of patients with defects in homologous recombinational repair is larger than initially expected. Citation Format: Simon N. Powell. Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY28-02
Clinical and Serologic Evolution of Multiple Penile Chancres in a Man Who Has Sex With Men
Authors: Yi Gao, Kenneth A. Katz
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Pratik B. Sandesara, Wesley T. O’Neal, Heval M. Kelli, Ayman Samman-Tahhan, Muhammad Hammadah, Arshed A. Quyyumi, Laurence S. Sperling
Journal: Diabetes Care (2017)

OBJECTIVE This study examined the prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS This analysis included 3,385 patients (mean age 69 ± 9.6 years; 49% male; 89% white) with HFpEF from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT). Diabetes and microvascular complications were ascertained by self-reported history and medical record review. Microvascular complications included neuropathy, nephropathy, and retinopathy. Outcomes included hospitalization, hospitalization for heart failure, death, and cardiovascular death. Cox regression was used to examine the risk of each outcome associated with diabetes and microvascular complications. RESULTS Of the 1,109 subjects (32%) with diabetes, 352 (32%) had at least one microvascular complication. Patients with diabetes and microvascular complications had an increased risk for hospitalization (no diabetes: referent; diabetes + no microvascular complication: hazard ratio [HR] 1.18, 95% CI 1.01, 1.37; diabetes + microvascular complications: HR 1.54, 95% CI 1.25, 1.89; P-trend &amp;lt;0.001), hospitalization for heart failure (no diabetes: referent; diabetes + no microvascular complication: HR 1.51, 95% CI 1.14, 1.99; diabetes + microvascular complications: HR 1.97, 95% CI 1.38, 2.80; P-trend &amp;lt;0.001), death (no diabetes: referent; diabetes + no microvascular complication: HR 1.35, 95% CI 1.04, 1.75; diabetes + microvascular complications: HR 1.73, 95% CI 1.22, 2.45; P-trend = 0.0017), and cardiovascular death (no diabetes: referent; diabetes + no microvascular complication: HR 1.34, 95% CI 0.96, 1.86; diabetes + microvascular complications: HR 1.70, 95% CI 1.09, 2.65; P-trend = 0.018). When the analysis was limited to participants who reported prior hospitalization for heart failure (n = 2,449), a higher risk of rehospitalization for heart failure was observed across diabetes categories (no diabetes: referent; diabetes + no microvascular complication: HR 1.40, 95% CI 1.01, 1.96; diabetes + microvascular complications: HR 1.78, 95% CI 1.18, 2.70; P-trend = 0.0036). CONCLUSIONS Diabetes is associated with adverse cardiovascular outcomes in HFpEF, and the inherent risk of adverse outcomes in HFpEF patients with diabetes varies by the presence of microvascular complications.
Inverse Relationship between Soluble RAGE and Risk for Bronchopulmonary Dysplasia
Authors: John T. Benjamin, Riet van der Meer, James C. Slaughter, Steven Steele, Erin J. Plosa, Jennifer M. Sucre, Paul E. Moore, Judy L. Aschner, Timothy S. Blackwell, Lisa R. Young
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study
Authors: Jessica J Liu, Chaim M Bell, John J Matelski, Allan S Detsky, Peter Cram
Journal: BMJ (2017)

Objective To estimate financial payments from industry to US journal editors.Design Retrospective observational study.Setting 52 influential (high impact factor for their specialty) US medical journals from 26 specialties and US Open Payments database, 2014.Participants 713 editors at the associate level and above identified from each journal's online masthead.Main outcome measures All general payments (eg, personal income) and research related payments from pharmaceutical and medical device manufacturers to eligible physicians in 2014. Percentages of editors receiving payments and the magnitude of such payments were compared across journals and by specialty. Journal websites were also reviewed to determine if conflict of interest policies for editors were readily accessible.Results Of 713 eligible editors, 361 (50.6%) received some (>$0) general payments in 2014, and 139 (19.5%) received research payments. The median general payment was $11 (£8; €9) (interquartile range $0-2923) and the median research payment was $0 ($0-0). The mean general payment was $28 136 (SD $415 045), and the mean research payment was $37 963 (SD $175 239). The highest median general payments were received by journal editors from endocrinology ($7207, $0-85 816), cardiology ($2664, $0-12 912), gastroenterology ($696, $0-20 002), rheumatology ($515, $0-14 280), and urology ($480, $90-669). For high impact general medicine journals, median payments were $0 ($0-14). A review of the 52 journal websites revealed that editor conflict of interest policies were readily accessible (ie, within five minutes) for 17/52 (32.7%) of journals.Conclusions Industry payments to journal editors are common and often large, particularly for certain subspecialties. Journals should consider the potential impact of such payments on public trust in published research.
Abstract 20215: Left Ventricular Assist Device Inflow Cannula-Mitral Alignment and Pump Migration Impact LVAD Dysfunction Over Long Term Support
Authors: Toshinobu Kazui, Andrew Bierhals, Andrew Zhang, Jason Greenberg, Angela D Keith, Akinobu Itoh, Gregory A Ewald, Scott C Silvestry
Journal: Circulation (2014)

Purpose: LVAD position at implant has long term implications with aligning the inflow cannula along the mitral valve axis and anchoring the pump as important goals. This study investigates the impa...
TCT-22 Evaluation of the SoundBite Crossing System in a coronary Chronic Total Occlusion (CTO) Acute Swine Model
Authors: Raja Hatem, Dimitri Karmpaliotis, Louis-Philippe Riel, Philippe Généreux, Juan Granada, Martin Brouillette, Stéphane Rinfret
Journal: Journal of the American College of Cardiology (2017)
Effectiveness of single-dose azithromycin to treat latent yaws: a longitudinal comparative cohort study
Authors: Oriol Mitjà, Camila González-Beiras, Charmie Godornes, Reman Kolmau, Wendy Houinei, Haina Abel, August Kapa, Raymond Paru, Sibauk V Bieb, James Wangi, Sergi Sanz, Kingsley Asiedu, Sheila A Lukehart, Quique Bassat
Journal: The Lancet Global Health (2017)

Treatment of latent yaws is a crucial component of the WHO yaws eradication strategy to prevent relapse and the resulting transmission to uninfected children. We assessed the effectiveness of single-dose azithromycin to treat patients with latent yaws.This population-based cohort study included children (age <20 years) living on Lihir Island, Papua New Guinea, with high-titre (rapid plasma reagin titre ≥1:8) latent or active yaws, between April, 2013, and May, 2015. Latent yaws was defined as lack of suspicious skin lesions or presence of ulcers negative for Treponema pallidum subsp pertenue on PCR, and active yaws was defined as ulcers positive for T pertenue on PCR. All children received one oral dose of 30 mg/kg azithromycin. The primary endpoint was serological cure, defined as a two-dilution decrease in rapid plasma reagin titre by 24 months after treatment. Treatment of latent yaws was taken to be non-inferior to that of active yaws if the lower limit of the two-sided 95% CI for the difference in rates was higher than or equal to -10%. This study is registered with ClinicalTrials.gov, number NCT01955252.Of 311 participants enrolled, 273 (88%; 165 with latent yaws and 108 with active yaws) completed follow-up. The primary endpoint was achieved in 151 (92%) participants with latent yaws and 101 (94%) with active yaws (risk difference -2·0%, 95% CI -8·3 to 4·3), meeting the prespecified criteria for non-inferiority.On the basis of decline in serological titre, oral single-dose azithromycin was effective in participants with latent yaws. This finding supports the WHO strategy for the eradication of yaws based on mass administration of the entire endemic community irrespective of clinical status.Newcrest Mining Limited and ISDIN laboratories.
A Case of Chest Pain and Transient Cardiac Arrest
Authors: Michael H. Chiu
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
TCT-765 Prevention of Restenosis with Adventitial Delivery of Torisel via Mercator MedSystems Bullfrog Catheter in Femoral Arteries of Swine
Authors: Athanasios Peppas, Kirk Seward, Karl Van Wygerden, Gerard Conditt, Armando Tellez, Serge Rousselle, Greg Kaluza, Juan Granada
Journal: Journal of the American College of Cardiology (2017)
Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population
Authors: Anthony Lopez, Anne-Marie Bouvier, Valérie Jooste, Vanessa Cottet, Gaëlle Romain, Jean Faivre, Sylvain Manfredi, Come Lepage
Journal: Gut (2017)

Objective Population-based studies on colorectal malignant polyps (MPs) are scarce. The aim of this study was to describe time trends in the incidence of colorectal MPs before and after the introduction of a colorectal mass-screening programmein 2003 and to assess outcomes (survival and recurrence) after endoscopic or surgical resection in patients with MPs. Design We included 411 patients with MPs diagnosed between 1982 and 2011 in a well-defined population. Age-standardised incidence rates were calculated. Univariate and multivariate 5-year recurrence and net survival analyses were performed according to gross morphology. Results Age-standardised incidence of MPs in patients aged 50–74 years doubled from 5.4 in 1982–2002 to 10.9 per 100 000 in 2003–2011. Pedunculated MPs were more frequently resected endoscopically (38.2%) than were sessile MPs (19.1%; p &lt;0.001). For patients with pedunculated MPs and a pathological margin ≥1 mm, the 5 -year cumulative recurrence rate did not differ significantly between surgical and endoscopic resection (8.2% and 2.4%, respectively). For patients with sessile MPs, it was 3.0% after firs t-line or second-line surgical resection, 8.6% after endoscopic resection and 17.9% after transanal resection (p=0.016). The recurrence rate decreased dramatically for patients with sessile MPs from 11.3% (1982–2002) to 1.2% (2003–2009) (p=0.010) and remained stable for pedunculated MPs at 4.6% and 6.7%, respectively. Five-year net survival was 81.0% when pathological margins were &lt;1 mm and 95.6% when ≥1 mm (p=0.024). Conclusion Outcomes following polypectomy in patients with a pathological margin ≥1 mm are similar to those following surgery in the general population. Endoscopic resection needs to be completed by surgery if pathological margins are less than 1 mm.
TCT-549 CHANGE DAPT: clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents
Authors: Clemens von Birgelen, Paolo Zocca, Liefke van der Heijden, Marlies Kok, Martin Stoel, Marc Hartmann, Frits de Man, J.Hans Louwerenburg, Marije Lowik, Iris Knottnerus, Gerard C.M. Linssen, Carine J.M. Doggen, K. Gert van Houwelingen
Journal: Journal of the American College of Cardiology (2017)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
Authors: A. Egeberg, M.B. Ottosen, R. Gniadecki, S. Broesby-Olsen, T.N. Dam, L.E. Bryld, M.K. Rasmussen, L. Skov
Journal: British Journal of Dermatology (2017)

Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking.To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima).The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics. We examined patients treated between 1 January 2007 and 31 March 2017. We used Kaplan-Meier survival curves and Cox regression to examine drug survival patterns.A total of 3495 treatment series (2161 patients) were included (adalimumab n = 1332; etanercept n = 579; infliximab n = 333; ustekinumab n = 1055 and secukinumab n = 196). Secukinumab had the highest number of PASI 100 (100% improvement from baseline Psoriasis Area and Severity Index) respondents, but also the lowest drug survival among all the biologics. Ustekinumab had the highest drug survival overall. There were no significant differences in discontinuation risk between originator and biosimilar versions of infliximab or etanercept. Treatment with higher than approved dosages was frequent for all drugs except for adalimumab and secukinumab. Adverse events (predominantly infections) were most frequent for secukinumab compared with the other agents.Ustekinumab was associated with the highest drug survival, and secukinumab with the lowest, although most patients on secukinumab were non-naïve. Switching from originator to biosimilar had no significant impact on drug survival, and the safety profiles were comparable. Adverse events occurred most frequently with secukinumab. Future studies are warranted to assess the long-term safety of novel biologics for psoriasis.
Preparação hospitalar e tratamento dos pacientes com febre hemorrágica vírica ou com variola no Instituto Lazzaro Spallanzani, Roma, Itália
Authors: G Ippolito, E Nicastri, M R Capobianchi, A Di Caro, N Petrosillo, V Puro
Journal: Eurosurveillance (2005)

Os casos americanos de anthrax em 2001 e o surto recente de sindrome respiratorio agudo severo (SRAS) aumentaram a necessidade de uma preparacao e resposta as infeccoes emergentes ou re-emergentes de forma natural e aos agentes patogenos disseminados deliberadamente. O presente relatorio descreve o modelo de resposta do Instituto nacional paras as doencas infecciosas (INMI, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italia) para o tratamento de pacientes infectados – ou suspeitos de se-lo – pela variola ou a febre hemorragica, seja no contexto de uma emissao deliberada do virus ou de uma infeccao de origem natural. 
Em Italia, o INMI e o hospital de referencia em termos de planos de preparacao e de resposta aos agentes infecciosos relacionados com ataques bioterroristas. Todos os quartos, simples ou duplos, estao equipados com pressao negativa do ar, portas reforcadas, filtros HEPA (high efficiency particulate air), assim como uma anticâmara totalmente equipada. Tambem esta disponivel uma unidade de alta seguranca, com um laboratorio annexo para os primeiros testes de diagnostico, para os casos esporadicos que necessitem isolamento. Para o transporte dos pacientes, o instituto dispoe de duas ambulancias totalmente equipadas e de duas macas isoladas com uma secao de pressao negativa. Os testes diagnosticos moleculares e tradicionais estao realizados actualmente nos laboratorios de bioseguridade de nivel 3/4. A educacao e formacao do pessoal hospitalar, a applicacao stricta das praticas de controle da infeccao e dispor de equipos de proteccao pessoal, sao recursos addicionais que permitem tratar os pacientes extremamente contagiosos, e manter uma equipe correctamente preparada para responder a surtos de grande escala.
FDG PET/CT in Immunoglobulin G4–Related Spinal Hypertrophic Pachymeningitis
Authors: Qian Zhao, Aisheng Dong, Yushu Bai, Yang Wang, Changjing Zuo
Journal: Clinical Nuclear Medicine (2017)

Abstract A 49-year-old woman complained of right upper back pain for 1 month. Serum tests showed increased erythrocyte sedimentation rate. Thoracic spinal MRI showed an epidural lesion at the T1–T4 level with inhomogeneous signal intensity on T2-weighted images, slightly higher signal intensity than spinal cord on T1-weighted images, and remarkable enhancement on enhanced T1-weighted images. Epidural malignant tumor was suspected. FDG PET/CT was performed showing increased FDG uptake of the lesion extending to the right T1–T2 and T2–T3 neural foramina. A decompressive posterior thoracic laminectomy with the lesion resection was performed. Immunoglobulin G4–related spinal hypertrophic pachymeningitis was confirmed by pathology.